© 2002 by Oxford University Press
Journal of the National Cancer Institute, Vol. 94, No. 10, 706-707,
May 15, 2002
© 2002 Oxford University Press
EDITORIAL |
Adenovirus Gene Therapy for Ovarian Cancer
Affiliation of author: University of St. Andrews, North Haugh, St. Andrews, U.K.
Correspondence to: Professor W. C. Russell, BSc., Ph.D., FRSE, Biomolecular Sciences Bldg., University of St. Andrews, North Haugh, St. Andrews, Fife, U.K. KY16 9ST (wcr@st-andrews.ac.uk).
Ovarian cancer is the leading cause of death from gynecologic malignancies and, although conventional chemotherapy provides some initial positive response, drug resistance can often occur within months. Thus, it is not surprising that other strategies are sought, and a number of groups have used virus gene therapy as one possible route to supplement conventional chemotherapy.
Adenovirus vectors have been used extensively for gene therapy because of their high infection efficiency in dividing and nondividing cells and the wide prevalence of the coxsackie-adenovirus receptors (CARs) in a variety of cells and tissues (1). For cancer gene therapy, three principal targets
REFERENCES